


Sygnia Itrix Solactive Healthcare 150 ETF

Global - Equity - General

31 March 2022



Portfolio Managers	Sygnia Asset Management
Inception	6 August 2021
Fund Size	R 594 Million
NAV Price	2 442 cents
Units in Issue	24 319 913

Investment Objective

Income Distribution

Trustees

To replicate the price and yield performance of the Solactive Developed Markets Healthcare 150 Index Bi-Annually (December and June)
Payment: 17 Jan 2022 - 4.50653 cents per unit
Standard Bank Trustees (021 441 4100)

Fund Information	
Classification	Regional - Equity - General
Asset Allocation	100% Offshore
NAV/Index Ratio	ca. 1/1000
Financial Year End	31 December
Index Tracking	Solactive Developed Markets Healthcare 150
Dividend Distribution	Semi-annual distribution
NAV Publication	Daily on sygnia.co.za
Portfolio Valuation	Close of relevant market
Foreign exchange source	World Market fix rate 16:00pm EST

Listing Information	
Exchange	JSE Limited
Exchange Code	SYGH
Trading Currency	ZAR
Portfolio Currency	USD
ISIN	ZAE000300521
RIC	SYGHJJ
Bloomberg Ticker	SYGH SJ Equity
Trading Hours	9:00 am - 16:50 pm
Transaction cut-off	JSE trading hours

Top 10 Holdings	
Instrument	Percent
UnitedHealth Group Ord Shs	6.3%
Johnson & Johnson Ord Shs	6.1%
Pfizer Ord Shs	3.8%
AbbVie Ord Shs	3.7%
Roche Holding Par Shs	3.7%
Eli Lilly Ord Shs	3.2%
Thermo Fisher Scientific Ord Shs	3.0%
Abbott Laboratories Ord Shs	2.7%
Novartis Ord Shs	2.7%
Merck & Co Ord Shs	2.7%

Asset Allocation		
Asset	Percent	Allocation
International Equity	99.5%	

Geographic Allocation		
Region	Percent	Allocation
United States	72.6%	
Switzerland	8.2%	
United Kingdom	4.3%	
Japan	3.9%	
Denmark	3.0%	
France	2.5%	
Germany	2.2%	
Australia	1.7%	
Other	1.6%	

Disclaimer

Sygnia Itrix (RF) (Pty) Ltd is a registered and approved Manager under the Collective Investment Schemes Control Act, 2002. Sygnia Itrix does not provide any guarantee with respect to the capital or return of the portfolio. Collective Investment Schemes (CIS) are generally medium to long-term investments. The value of participatory interests may go down as well as up and past performance is not necessarily an indicator of future performance. CIS are traded at ruling prices and can engage in borrowing and scrip lending. ETFs trade on stock exchanges and may therefore incur additional costs associated with listed securities. Unlike a unit trust, which can be bought or sold only at the end of the trading day, an ETF can be traded intraday, during exchange trading hours. ETFs may invest in foreign securities, which may be exposed to macroeconomic, settlement, political, tax, illiquidity and foreign exchange risks. Additional information on the Index including its performance and tracking error can be viewed on the relevant Fund Fact Sheets on www.sygnia.co.za. A schedule of fees and charges may be requested via admin@sfs.sygnia.co.za or 0860 794 642 (0860 SYGNIA). The complete terms and conditions of your ETF investment are contained in the fund's offering circular, pre-listing statement, programme memorandum and/or supplemental. These documents may be obtained from www.sygnia.co.za or on request from Sygnia. Nothing in this document shall be considered to state or imply that the Fund is suitable for a particular type of investor.

Sector Allocation		
Sector	Percent	Allocation
Health Care	98.4%	
Consumer Discretionary	0.7%	
Consumer Staples	0.4%	
Materials	0.1%	
Other	0.5%	

Portfolio Performance Analysis				
Period	Sygnia Itrix Solactive Healthcare 150	Solactive Developed Markets Healthcare 150 Index (ZAR)**	Solactive Developed Markets Healthcare Index	Sygnia Itrix Solactive Healthcare 150 ETF (TR)
Since Inception	-1.2%	-1.2%	0.6%	-1.0%

Performance of the fund is calculated by Sygnia Asset Management as at reporting date.
*A positive performance in currency reflects a depreciation of ZAR against base currency and vice versa.
**Price return.

Fees	
Management Fee	0.50%
VAT	0.08%
Other costs	-0.08%
Total Expense Ratio (TER)	0.50%
Transaction Costs (TC)	Not applicable at this time
Total Investment Charge (TIC)	Not applicable at this time

Sygnia Itrix Solactive Healthcare 150 ETF

Fund Commentary

Global - Equity - General

1st Quarter 2022

Market Performance

March saw central banks, surging prices and global investor enthusiasm for China compete for our attention with the atrocities on the ground as the war in Ukraine rumbled past the one-month mark. President Putin's invasion ousted Covid as public enemy number one as the somewhat shell-shocked analysts of the world recalibrated their global macro-economic stances.

The Russian invasion of the Ukraine has escalated beyond most people's wildest nightmares.

War atrocities sent shock waves throughout the world as we witnessed the bombing of civilian areas in key Ukrainian cities, and financial markets responded with a dramatic sell-off across risk assets. The West has responded with sanctions, turning Russia's dominant position in world energy into the elephant in the room. Russia is the world's third largest exporter of oil, and Europe buys around 60% of Russia's oil exports. The continuation of the war is pitting the West's own domestic financial interests against their political interests abroad. As Western powers put more pressure on the Russian energy economy in recent weeks, oil reached its highest level since 2008 (\$139 per barrel) in March. While the US failed in a lone attempt to ban Russian oil, US Secretary of State Antony Blinken is still engaging with European and Japanese allies to test appetites for a more concerted ban. New talk of compromise from Moscow and Kyiv for Ukraine's status outside of NATO have lifted global markets, but the odds of a breakthrough are not quite favourable yet. Ultimately, the war's impact on global growth and inflation will depend on how long it lasts. And it's not just oil: China-Europe rail routes are used to move more than a million containers via Russia across the 6 000-plus miles of railway that link western Europe to eastern China. These containers must now find new routes via sea, adding to costs and threatening to worsen global supply-chain chaos. European natural gas prices shot up 34% as Putin said he would only accept payment in rubles. No mention has yet been made of Russian gas import restrictions, which would pose major issues for European economies, as 40% of their gas needs are met by Russia. Sanctions on the export of natural gas from Russia to the EU or UK are unlikely.

Global inflation is rising as war related driven supply disruptions replace Covid disruptions and the US is worst hit. In the first hike since 2018, the Federal Open Market Committee (FOMC) raised rates by 25 bps to 0.5%. The Fed ramped up its rate-hike projections to seven overall for 2022, with an additional three or four in 2023. Powell left the door open to a striking 50bps hike in the sequence. To maintain its credibility without crashing the economy, the Fed needs to talk up the rate-hiking cycle – a high-risk move with little hope of completion. With the Fed already on the monetary-policy back foot, Treasury is unlikely to oppose inflation eating away at the national debt pile for a while, either; avoiding a recession is paramount. Rising yields have seen US home affordability at its worst level since 2007, which will slow housing activity, house price increases and growth via a lower wealth effect. The US is in a very difficult position.

China's Hang Seng Technology Index fell nearly 70% from its peak, and Chinese stocks entered their deepest bear market since 2008 as concerns about the country's ties with Russia, a surge in Covid cases and continued regulatory pressure on the technology sector sent shares on a downward spiral.


Moscow had sought military equipment from Beijing, and the US warned China of consequences for supporting the Kremlin. China's Foreign Minister, Wang Yi, says he wants to avoid US sanctions, and the US and China held high-level in-person talks that they described as "substantial" and "constructive". On top of the delicate situation around Russia, US regulators continue to pursue a multiple-year impasse over audit access to Chinese companies with US investors. The US Securities and Exchange Commission named its first Chinese stocks as part of a crackdown on foreign firms that have refused to open their books to US regulators, heightening delisting risks. The battle with the US over existing issues and now Russia comes as China is weakened domestically by yet another Covid outbreak. Nearly 30 million people are under lockdown in China as surging Covid-19 cases have led to the return of mass tests on a scale not seen since the start of the pandemic, leading to worries about a slowdown in growth and further global supply disruptions.

China has reached the equivalent of Mario Draghi's "whatever it takes" moment of the Grexit crisis. China's state council has addressed all the biggest concerns for investors, pledging to keep Chinese capital markets stable, support overseas stock listings, work with the US, address the fragile property development sector and end Big Tech regulations. Coupled with positive fundamentals, the strong rhetoric supporting the economy that key stakeholders want to see in China is shaping up as a catalyst.

South Africa is of course expected to be hit by the rise in energy prices and then by raised inflation. The silver lining is that inflation pressures are muted for an economy with growth as low as South Africa's. The SARB's monetary policy committee (MPC) opted to hike the repo rate by a further 25bps, to 4.25%. Three of the MPC members were in favour of a 25bps hike, while two pushed a more hawkish 50bps rise. While the SARB will continue to raise rates, they are unlikely to do so too quickly, and we think bond yields will not price in inflation concerns for too long. Core inflation for February remained steady at 3.5% year-on-year. The strong rand will certainly help cushion the blow of rising oil prices.

Our global recovery base for this year remains intact, driven by recovering economic activity as a result of eased Covid restrictions. Equity is expected to continue a rotation to value, with sustained emerging market outperformance due to rising real bond yields as global growth remains resilient – if lower than expected – at the start of the year.


RISK PROFILE



LESS RISK/
RETURN

MORE RISK/
RETURN

TIME HORIZON



Fund Performance

The Sygnia Itrix Solactive Healthcare 150 ETF delivered -12.1% for the quarter, marginally above its benchmark, the Solactive Developed Markets Healthcare 150 Index. The Fund benefitted from exposure to Abbvie Inc, AstraZeneca PLC and Bristol-Myers Squibb Co, while its exposure to Pfizer Inc, Abbott Laboratories and Thermo Fisher Scientific Inc detracted from performance.

There were several changes to the tracked index's constituents over the period, including the addition of Tenet Healthcare Corp, Envista Holdings Corp and Tandem Diabetes Care Inc and the removal of Novozymes, Chr. Hansen Holding and CRISPR Therapeutics.

The Fund remains true to its investment objective of delivering returns that mirror those of the Solactive Developed Markets Healthcare 150 Index.

Disclaimer

Sygnia Itrix (RF) (Pty) Ltd is a registered and approved Manager under the Collective Investment Schemes Control Act, 2002. Sygnia Itrix does not provide any guarantee with respect to the capital or return of the portfolio. Collective Investment Schemes (CIS) are generally medium to long-term investments. The value of participatory interests may go down as well as up and past performance is not necessarily an indicator of future performance. CIS are traded at ruling prices and can engage in borrowing and scrip lending. ETFs trade on stock exchanges and may therefore incur additional costs associated with listed securities. Unlike a unit trust, which can be bought or sold only at the end of the trading day, an ETF can be traded intraday, during exchange trading hours. ETFs may invest in foreign securities, which may be exposed to macroeconomic, settlement, political, tax, illiquidity and foreign exchange risks. Additional information on the Index including its performance and tracking error can be viewed on the relevant Fund Fact Sheets on www.sygnia.co.za. A schedule of fees and charges may be requested via admin@sfs.sygnia.co.za or 0860 794 642 (0860 SYGNIA). The complete terms and conditions of your ETF investment are contained in the fund's offering circular, pre-listing statement, programme memorandum and/or supplemental. These documents may be obtained from www.sygnia.co.za or on request from Sygnia. Nothing in this document shall be considered to state or imply that the Fund is suitable for a particular type of investor.

Important information to consider before investing

Investment Objective and Strategy

The objective of the Sygnia Itrix Solactive Healthcare 150 ETF is to provide an investment vehicle to investors who want to achieve long term capital appreciation in tracking the performance of the Solactive Developed Markets Healthcare 150 Index (.SDMH150P) (“benchmark index”).

In order to achieve this objective, the Sygnia Itrix Solactive Healthcare 150 ETF shall track the Solactive Developed Markets Healthcare 150 Index (.SDMH150P) Index as closely as practically and feasibly possible by buying securities that substantially make up the index at similar weighting as they are included in the Index. Whenever the Index gets rebalanced, the Portfolio will be rebalanced to align its holdings to that of the benchmark and to the extent that its performance will not deviate from its benchmark.

Balancing risk and reward

The Fund has a 100% strategic allocation to global equities. The structure of the Fund is dictated by the composition of the Solactive Developed Markets Healthcare 150 Index and managed with the aim to produce the same level of income as that produced by the index. Investors are alerted to the fact that the Fund is not a general equity product, but one with a specific focus, and thus a specific risk and return profile. For a change in the index constituents, please refer to the published SENS. Index Performance data can be sourced from Bloomberg, Reuters, other data providers and at www.sygnia.co.za.

Collective Investment Schemes (CIS) are generally medium-to long-term investments. The value of units may go down as well as up and past performance is not necessarily an indicator of future performance. CIS are traded at ruling prices and can engage in borrowing and scrip lending. Equity markets are volatile and the price of equities fluctuate based on a number of factors such as changes in the economic climate, general movements in interest rates and the political and social environment which will also affect the value of the securities held in the unit trust, thereby affecting the overall value of the unit trust. There are regulations in place which limit the amount that a unit trust may invest in securities, thereby spreading the risk across securities, asset classes and companies. The fund may also be exposed to liquidity risk. This relates to the ability of the unit trust to trade out of a security held in the portfolio at or near to its fair value.

Annualised performance figures represent the geometric average return earned by the fund over the given time period. Unannualised performance represents the total return earned by the fund over the given time period, expressed as a percentage.

Performance is calculated based on the NAV to NAV calculation of the portfolio. Individual investor performance may differ as a result of initial fees, the actual investment date and dividend withholding tax.

Fees

A schedule of fees and charges is available on request from Sygnia Itrix. Permissible deductions may include management fees, brokerage, STT, auditor's fees, bank charges and trustee fees. Sygnia Itrix ETFs are Exchange Traded Funds that trade on stock exchanges and may therefore incur additional costs associated with listed securities. Sygnia Itrix does not provide advice and therefore does not charge advice fees.

What is the Total Expense Ratio (TER) and Transaction Costs (TC)?

The total expense ratio (TER) is the annualised percentage of the fund's average assets under management that has been used to pay the fund's actual expenses over the past three years. Transaction costs are a necessary cost in administering the fund and impact fund returns. They should not be considered in isolation as returns may be impacted by many other factors over time, including market returns, the type of financial product, the investment decisions of the investment manager and the TER. Since fund returns are quoted after the deduction of these expenses, the TER and Transaction Costs should not be deducted again from the published returns. A higher TER does not necessarily imply a poor return, nor does a low TER imply a good return.

Foreign Securities

The fund invests in foreign securities, which may be exposed to macroeconomic, settlement, political, tax, reporting or illiquidity risk factors that may be different to similar investments in South African markets. Fluctuations or movements in exchange rates may cause the value of underlying investments to go up or down.

Cumulative Investment Performance

Cumulative investment performance is for illustrative purposes only. The investment performance is calculated by taking all ongoing fees into account for the amount shown, with income reinvested on the reinvestment date.

Exchange Traded Funds vs Unit Trusts

Whilst both unit trusts and ETFs are regulated and registered under the Collective Investment Scheme Control Act, ETFs trade on stock exchanges just like any other listed, tradable security. Unlike a unit trust, which can be bought or sold only at the end of the trading day, an ETF can be traded intraday, during exchange trading hours.

How are NAV prices calculated?

Net Asset Value (NAV) prices are calculated on a net asset value basis, which is the total market value of all assets in the portfolio including any income accruals and less any permissible deductions from the portfolio divided by the number of units in issue. The price at which ETFs trade on an Exchange may differ from the NAV price published at the close of the trading day, because of intraday price movements in the value of the constituent basket of securities.

Disclaimer

Sygnia Itrix (RF) (Pty) Ltd is a registered and approved Manager under the Collective Investment Schemes Control Act, 2002 (Act No 45 of 2002). Mellon Capital Management Company is the appointed investment manager, registered with the Securities and Exchange Commission (“SEC”). Sygnia Itrix does not provide any guarantee with respect to the capital or return of the portfolio. Nothing in this minimum disclosure document will be considered to state or imply that the collective investment scheme or portfolio is suitable for a particular type of investor.

This document is for information purposes only and does not constitute or form any part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase any particular investment. Whilst reasonable care was taken in ensuring that the information contained in this document is accurate. Sygnia Limited, or any of its affiliates do not accept any liability in respect of any damages and/or loss (whether direct or consequential) or expense of any nature which may be suffered as a result of reliance, directly or indirectly, on the information in this document. Additional information such as fund prices, brochures, application forms and a schedule of fees and charges be requested via admin@sfs.sygnia.co.za or 0860 794 642 (0860 SYGNIA).

You should be aware that certain transactions give rise to substantial risk. Product values may be affected by market values, interest rates, exchange rates, volatility, dividend yields and issuer credit ratings. The complete terms and conditions of your ETF investment are contained in the fund's offering circular, pre-listing statement, programme memorandum and/or supplemental. These documents may be obtained from www.sygnia.co.za or on request from Sygnia.

Sygnia Limited and any of its affiliates may make markets or hold units in the fund or hold positions in the investments in which the fund invests. As set out in the offering circular, the sale of securities is subject to restrictions in some jurisdictions. In particular, any direct or indirect distribution of this document into the United States, Canada or Japan, or to U.S. persons or U.S. residents, is prohibited.

Index Disclaimer

The Index is a product of S&P Dow Jones Indices LLC or its affiliates (“SPDJ”) and has been licensed for use by Sygnia Itrix. Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”); and these trademarks have been licensed for use by SPDJ and sublicensed for certain purposes by Sygnia Itrix.

The Fund is not sponsored, endorsed, sold or promoted by SPDJ, Dow Jones, S&P, their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the Index.

CAPE TOWN: 7th Floor, The Foundry, Cardiff Street, Green Point, 8001 T +27 21 446 4940

JOHANNESBURG: Unit 40, 6th Floor Katherine & West Building, West Street, Sandton, 2196 T +27 10 595 0550

DURBAN: Office 2, 2nd Floor Ridgeview, 1 Nokwe Avenue, Ridgeside, Umhlanga Ridge, 4319 T +27 31 001 0650

www.sygnia.co.za | info@sygnia.co.za

SYGNIA ITRIX (RF) (PTY) LTD
Registration No. 2004/035580/07

Minimum Disclosure Document - Issue Date: 11 Apr 2022

Sygnia 